Immunotherapy of house dust mite allergy
- PMID: 28853977
- PMCID: PMC5647988
- DOI: 10.1080/21645515.2017.1364823
Immunotherapy of house dust mite allergy
Abstract
House dust mite (HDM) is a predominant source of indoor aeroallergen worldwide, which induces allergic diseases including allergic rhinoconjunctivitis, allergic asthma, atopic eczema and other allergic skin diseases. Allergen specific immunotherapy (AIT) is the only potential disease-modifying treatment of HDM allergic subjects. However, AIT remains underused due to no universally accepted allergen standardization and a shortage of rigorous clinical studies to confirm safety and efficacy. With the effort of doctors and researchers in allergy field, efficacy, safety, standardization and strategy of AIT are being continuously developed. This review presents the updated research based on recently published trials and meta-analyses.
Keywords: efficacy; house dust mite; immunotherapy; safety.
References
-
- Dust mite allergens and asthma–a worldwide problem. J Allergy Clin Immunol. 1989;83(2 Pt 1):416-27. - PubMed
-
- Bousquet J, Dahl R, Khaltaev N. Global Alliance against Chronic Respiratory Diseases. Eur Respir J. 2007;29(2):233-9. PMID:17264322 - PubMed
-
- Bateman ED, Hurd SS, Barnes PJ, et al.. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143-78. PMID:18166595 - PubMed
-
- Chen J, Zhao Y, Li B, Zhang Q, Wan L, Liu J, Tian X, Li G, Zhou J, Zhang L et al.. A multicenter study of the clinical features of allergic rhinitis in central China. Am J Rhinol Allergy. 2014;28(5):392-6. PMID:25198025 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical